A Phase 1 and 2a open-label trial to evaluate the safety tolerability pharmacokinetics pharmacodynamics immunogenicity and antitumor activity of LAVA-1207 a PSMA-targeting bispecific .d-T cell engager alone or with low dose interleukin-2 or Pembrol

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Prostate Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male
  • Other Inclusion Criteria:
    1) Male patient with mCRPC as defined by PCWG3 criteria (histologically confirmed adenocarcinoma; adenocarcinoma with =10% small-cell or neuroendocrine features is allowed). 2) Brain metastasis are allowed as long as the patient’s symptoms are well con

You may not be eligible for this study if the following are true:

  • 1) Other malignancies within the last 2 years except adequately treated carcinoma in situ, basal or squamous cell skin carcinoma. 2) Uncontrolled or severe intercurrent medical condition. 3) Positive serological testing for human immunodeficiency


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.